Epix Medical has granted Bracco Imaging a worldwide, nonexclusive, royalty-bearing license for the use of certain patents. The $10 million deal covers patents related to Bracco’s Multihance, which is used to image the liver and central nervous
Epix Medical has granted Bracco Imaging a worldwide, nonexclusive, royalty-bearing license for the use of certain patents. The $10 million deal covers patents related to Bracco’s Multihance, which is used to image the liver and central nervous system. In May 2000, Epix granted Schering a worldwide, nonexclusive, royalty-bearing license for the sale of Eovist, an investigational MRI contrast agent for liver imaging. The patents are owned by the Massachusetts General Hospital and licensed exclusively to Epix, which will receive upfront payments made up of a license fee, royalties on past sales, prepayment of future royalties, and a contingent license fee based on marketing approval of Multihance in the U.S.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.